AC-203, also known as CCP-020, is advancing to a Phase 2 clinical trial as a potential treatment for patients with…
Articles by Alice Melao
A rare case of hair loss associated with PLEC gene mutation and epidermolysis bullosa simplex with muscular dystrophy…
Data from a Phase 2 trial validated a new five-point Investigator’s Global Assessment (IGA) scale for the clinical evaluation of…
Skin colonization by bacteria resistant to Bactroban (mupirocin) is frequent among patients with epidermolysis bullosa (EB), and may be…
The systemic administration of collagen VII protein can reduce bacteria in the skin of mice with epidermolysis bullosa (EB), according…
Diacerein, which is a commercially available medicine used to treat osteoarthritis, also may hold therapeutic potential to treat blistering in…
InMed Pharmaceuticals has filed a provisional patent application covering its proprietary cannabinoid manufacturing system based on E. coli bacteria. This is…
The U.S. Food and Drug Administration (FDA) recently recommended Abeona Therapeutics accelerate the clinical development program of its gene therapy candidate…
The U.S. Food and Drug Administration has granted a Rare Pediatric Disease Designation to EB-101,  Abeona Therapeutics’ treatment for…